1 [DP1] blocker) to statin-based therapies does not significantly decrease the risk of CVD events but increases the risk of serious adverse events. Here, we tested whether, and how, niacin beneficial effects in vivo myocardial ischemia requires the activation of the PGD2/DP1 axis. Myocardial infarction (MI) was reproduced by ligation of the left anterior descending branch of the coronary artery in mice. We found that niacin increased PGD2 release in macrophages and shifted macrophages to M2 polarization both in vitro and in vivo by activation of DP1 and accelerated inflammation resolution in zymosan-induced peritonitis in mice. Moreover, niacin treatment facilitated wound healing and improved cardiac function after MI through DP1-mediated M2 bias and timely resolution of inflammation in infarcted hearts. In addition, we found that niacin intake also stimulated M2 polarization of peripheral monocytes in humans. Collectively, niacin promoted cardiac functional recovery after ischemic myocardial infarction through DP1-mediated M2 polarization and timely resolution of inflammation in hearts. These results indicated that DP1 inhibition may attenuate the cardiovascular benefits of niacin. This article has not been copyedited and formatted. The final version may differ from this version.
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INTRODUCTION
Niacin, also known as vitamin B3 or nicotinic acid, is a safe, broad-spectrum lipid-lowering agent used to prevent cardiovascular events (Dunbar and Goel, 2016) . Niacin inhibits free fatty acid (FFA) release from adipocytes (Carlson, 1963) and reduces plasma FFA levels in humans during fasting (Carlson and Oro, 1962) through its specific receptor GPR109A(Soga et al., 2003; Tunaru et al., 2003; Wise et al., 2003) . Niacin also suppresses hepatic low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and triglyceride (TG) synthesis through inhibition of diacylglycerol acyltransferase 2 (Ganji et al., 2004) and increases plasma high-density lipoprotein cholesterol (HDLc) independent of the GRR109A receptor or FFA suppression (Knouff et al., 2008; Zhang et al., 2012) . In addition, niacin displays multiple anti-inflammation properties, including regulation of the expression of cell adhesion molecules (Tavintharan et al., 2009) , nuclear receptors and scavenger receptors (Rubic et al., 2004; Knowles et al., 2006) , through mechanisms that are unrelated to its effects on HDLc (Lukasova et al., 2011) . Moreover, niacin suppresses atherogenesis in hyperlipidemic mice through GPR109A-mediated suppression of immune cells (Lukasova et al.,2011) .
However, one major limitation of niacin is its induction of dermal side effects, e.g., facial flushing (Dunbar and Gelfand, 2010) , resulting from stimulation of the GPR109A receptor in skin immune cells (Benyo et al., 2005) . Vasodilatory prostaglandin (PG) D2, perhaps PGE2 as well, secreted in inflammatory cells, such as Langerhans cells, is thought to be involved in niacin-induced flushing through PGD2 receptor subtype 1 (DP1) (Hanson et al., 2010) . PGD2 is an arachidonic acid metabolite derived from sequential reaction This article has not been copyedited and formatted. The final version may differ from this version.
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Two distinct PGD2 synthases (PGDSs), the haematopoetic PGDS (H-PGDS) and the lipocalin PGDS (L-PGDS), mediate the last regulatory steps in the biosynthetic pathway of PGD2 production (Urade and Eguchi, 2002; Aritake et al., 2006) . PGD2 interacts mainly with two G-protein-coupled receptors: the DP1 receptor stimulates adenylyl cyclase through Gɑs, whereas DP2 [initially called chemoattractant receptor T helper type 2 (CRTH2)] inhibits adenylyl cyclase through Gɑi and increases intracellular Ca 2+ (Malki et al., 2005; Spik et al., 2005) . DP1 and DP2 are linked to different signaling pathways and appear to have distinct functions within the immune system (Kostenis and Ulven, 2006) . DP1 antagonism suppresses niacin-induced vasodilation in both mice and humans (Cheng et al., 2006) . Many studies have shown that cyclooxygenase-2-derived PGD2 promotes resolution of inflammation (Rajakariar et al., 2007) . DP1 is highly expressed in monocytes and macrophages (Rajakariar et al., 2007; Sandig et al., 2007) , and PGD2-induced macrophage M2 polarization facilitates inflammatory resolution through DP1-mediated suppression of Janus kinase 2 (JAK2)/signal transducer and activator of transcription (STAT) 1 signaling (Kong et al., 2016) . However, whether niacin shapes macrophage polarization and accelerates inflammatory resolution through PGD2 release remains unclear.
In the recent Heart Protection Study 2-Treatment of HDLc to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial, niacin therapy, combined with laropiprant (a DP1 antagonist), did not markedly decrease the risk of major cardiovascular events, but did increase the risk of serious side effects (Group et al., 2014) . However, it is unclear whether the cardiovascular benefits of niacin can be confounded by DP1 inhibition (Song and FitzGerald, 2013; Dunbar and Goel, 2016) . In this study, we evaluated the effects of This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on January 5, 2017 as DOI: 10.1124/jpet.116.238261 at ASPET Journals on January 15, 2017 jpet.aspetjournals.org Downloaded from niacin on PGD2 secretion and monocyte/macrophage M2 polarization through DP1 activation in mice using zymosan-induced peritonitis and myocardial infarction mouse models and analysis of the effects of niacin intake in humans. Our findings provide important insights into the effects of niacin on myocardial recovery from ischemic injury through activation of the DP1 receptor, suggesting that DP1 blockers may undermine the cardioprotective effects of niacin.
MATERIALS AND METHODS
Animals DP1 F/F mice were maintained on a C57BL/6 genetic background and crossed with C57BL/6 LysM Cre mice to generate DP1 F/F Lys Cre mice; these mice are referred to as Mac-DP1 KO mice (Kong et al., 2016) . DP1 F/F littermates (hereafter referred to as WT mice) were used as experimental controls. All animals were maintained and used in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Institute for Nutritional Sciences, University of Chinese Academy of Sciences.
Reagents
IFNγ and IL-4 were purchased from Peprotech (Rocky Hill, NJ, USA). LPS, niacin, zymosan and thioglycolate were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Peritoneal macrophage isolation and treatment
Peritoneal macrophages were induced and prepared by an intraperitoneal (i.p.) injection of 3% Brewer's thioglycolate as described previously (Yang et al., 2010) . Macrophages were allowed to adhere overnight (37°C, 5% CO2) and washed with fresh medium to remove unattached cells before use. Macrophage polarization was subsequently induced with LPS This article has not been copyedited and formatted. The final version may differ from this version.
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(1 μg/mL) plus IFN (20 ng/mL) or IL-4 (20 ng/mL) and analyzed by reverse transcription polymerase chain reaction (RT-PCR) or western blotting, as described below. All primers used for RT-PCR are described in Tables 2 and 3 .
MI mouse model
Left anterior descending (LAD) artery ligation was used in mice to induce myocardial infarction. Briefly, both male and female (6-8 weeks of age) mice were anesthetized with isoflurane (2%) using an induction chamber, and the LAD coronary artery was completely ligated to induce left ventricular ischemia .
Cell sorting from post-MI hearts
Mice were anesthetized and intracardially perfused with 40 mL ice-cold phosphate-buffered saline (PBS) to exclude blood cells. The heart was dissected, minced with fine scissors, and enzymatically digested with a cocktail of collagenase I (450 U/mL), collagenase XI (125 U/mL), DNase I (60 U/mL), and hyaluronidase (60 U/ mL; Sigma-Aldrich) for 1.5 h at 37°C with gentle agitation. After digestion, the tissue was triturated and passed through a 70-μm cell strainer. Leukocyte-enriched fractions were isolated by 37-70% Percoll (GE Healthcare, Piscataway, NJ, USA) density gradient centrifugation, as described elsewhere (Yan et al., 2013) . Cells were removed from the interface and washed with RPMI-1640 cell culture medium prior to staining with anti-CD45 and anti-CD11b antibodies and sorting into internal diameter at end diastole (LVDD) and end systole (LVDS), as well as the interventricular septal wall thickness and posterior wall thickness.
Flow cytometry
Isolated peripheral blood cells and leukocytes isolated from the heart were analyzed by flow cytometry. To block nonspecific binding of antibodies to Fcγ receptors, isolated cells were first incubated with anti-CD16/32 antibody (BD Bioscience) at 4°C for 5 min.
Subsequently, the cells were stained with a mixture of the following antibodies at 4°C for 30 min: anti-CD45-PE, anti-CD11b-FITC, anti-Ly6G-PE-Cy7, anti Ly6C-APC (eBioscience), anti-F4/80-BV421, anti-CD206-APC (BioLegend). Human peripheral blood monocytes were defined as SSClow CD14high cells. After staining with 7-amino-actinomycin D (Sigma) to discriminate dead cells, flow cytometry was performed on a FACSCalibur (BD Bioscience) and the data analyzed with FlowJo software (v.9).
PGD2 extraction and analysis
Cell supernatants or peritoneal exudates (500 μL) were used for PG extraction after protein quantification, as previously reported (Lu et al., 2015) . An internal standard separation was performed on a Agilent ZORBAX SB-Aq columns (3.0×250mm, 5um) HPLC column, using 0.1% acetic acid in water (mobile phase A ) and acetonitrile ( mobile phase B ) as the mobile phase for binary gradient elution. The column flow rate was 0.4mL/min; the column temperature was 25°C, and the autosampler was kept at 4°C. The binary elution gradient was 30% B to 53% B in 15minutes, and then to 90% B in 1 minute, maintained at 90% B for 3 minutes. The column was equilibrated for 10 min with the initial solvent composition between injections. PGD2 was detected and quantified in negative ion mode, and the electrospray potential was maintained at -4.5 kV and heated to 500°C. For MS-MS analysis, PGD2/internal standards were subjected to collision-induced fragmentation. PG production was normalized to total protein.
PGDM Analysis
Urinary prostanoid metabolite PGDM was extracted and quantitated as previously reported (Song et al., 2008) . In brief, mouse urine was collected for 24 hours in metabolic cages with fasting treatment after niacin or CMC treatment from the third day post MI. Samples (100μl) were spiked with internal standard (10μl [ 2 H6 ]Tetranor PGDM) contained in acetonitrile. Two times of the urine volume of an aqueous solution of methoxy-amine HCl
(1 g/ml) was added and allowed to stand for 30 min at room temperature and then make capacity to 1ml by water. The solid phase extraction cartridge was conditioned with 1 ml of acetonitrile and equilibrated with 1 ml of water. The sample was applied to the cartridge, which was then washed with 1 ml of 5% acetonitrile in water and dried with vacuum for 15 min. The analyte and internal standard were eluted from the cartridge using 1 ml of 5% acetonitrile in ethylacetate. The eluate was collected and dried under a gentle stream of nitrogen. The resulting residue was then dissolved in 100μl 10% ACN in water and passed This article has not been copyedited and formatted. The final version may differ from this version.
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through small centrifugal filters with a 0.2-μm nylon membrane prior to analysis by mass spectrometry. The urinary creatinine was used to normalize the prostaglandin metabolites.
Collection of Human Plasma and Urine
Sixteen healthy volunteers (20-30 years old) without taking any NSAIDs within one week, were administered niacin (500 mg/day, orally) for three days. Peripheral blood samples were collected 12 hours before and after niacin intake. Urine samples were collected at Each sample was analyzed in triplicate and normalized to a reference RNA. PCR products were confirmed by a single band of expected size on a 2% agarose gel. The primer sequences for PCR are summarized in Tables 2 and 3 .
Western blotting
This article has not been copyedited and formatted. The final version may differ from this version. Sigma-Aldrich) were used as a loading control. The membranes were then incubated in horseradish peroxidase (HRP)-labeled secondary antibodies in blocking buffer for 2 h.
Blots were developed using an enhanced chemiluminescence reagent (Thermo Scientific, Waltham, MA, USA).
Statistical Analysis
All data are expressed as the means ±SEM. Data were analyzed in GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA). Two-tailed student's t-testing and analysis of variance were used for comparisons between different groups. P-values < 0.05 were considered statistically significant. , 2016) . Similarly, here we found that niacin pre-treatment depressed LPS/IFNγ-induced STAT1 activation ( Fig. 1D ) and enhanced IL-4-induced STAT6 activation (Fig. 1E ) in macrophages in a dose-dependent manner, indicating niacin promotes macrophage polarization toward M2 status. Notably, these effects were disrupted by DP1 deletion (Fig. 1, F and G) . Therefore, our findings indicated that niacin modulated macrophage polarization via activation of the PGD2/DP1 axis.
Niacin accelerates resolution through DP1 in a zymosan-induced mouse model of peritonitis
Next, we examined the effect of niacin on zymosan-induced peritonitis in mice. Niacin (600mg/kg) (Wang et al., 1990; Nagai et al., 1994; Godin et al., 2012) , was administered to mice 24 h after zymosan challenge ( Fig. 2A) , and peritoneal macrophages were isolated for gene expression analysis. Hematopoietic-type PGD synthase (H-PGDS) and DP1 expression levels were increased in peritoneal macrophages from zymosan-treated mice (Fig. 2B) .
Notably, niacin reduced both total infiltrated inflammation cells and macrophages at the later stages of zymosan-induced peritonitis in WT mice (Fig. 2, C and D) , thereby accelerating resolution. Additionally, niacin markedly increased the CD11b + F4/80 + CD206 + macrophage ratio (M2-like) at the resolution phase (both 48 and 72 h) in zymosan-treated mice ( Fig. 2E) . Moreover, consistent with our observations in vitro, niacin also suppressed pro-inflammatory gene expression [i.e., tumor necrosis factor-alpha (TNF)] and induced anti-inflammatory gene expression [i.e., arginase 1 (Arg1), chitinase 3-like 3 (YM1) and CD206, mannose receptor, C type 1 (MRC1)] in peritoneal macrophages from WT mice (Fig.   2 , F-I). None of these alterations were observed in Mac-DP1 KO mice (Fig. 2, C-G) . Thus, niacin facilitated inflammatory resolution by promoting DP1-mediated macrophage polarization toward an M2-like state.
Niacin improves post-MI recovery by promoting DP1-mediated inflammatory resolution
We have confirmed that there was an increase of PGD2 in ischemic heart post MI (Fig. 3A) .
Again, niacin increased total body PGD2 production in mice, also upregulated both H-PGDS and DP1 expression in macrophages recruited to infarcted hearts at day 14 after experimental MI (Fig. 3, B and C) . Interestingly, niacin alleviated the inflammatory response to ischemia and accelerated resolution by reducing the infiltration of CD45 + leukocytes and CD11b + F4/80 + macrophages to the infarcted hearts in WT mice on days 7 and 14 after MI (Fig. 3, D and E, and Supplemental Fig. 1) . Moreover, niacin also reduced the CD11b + F4/80 + CD206macrophage ratio (M1-like) but increased the CD11b + F4/80 + CD206 + macrophage ratio (M2-like) in WT mice on days 7 and 14 after MI (Fig. 3, F and G) , suppressed the expression of pro-inflammatory genes (i.e., IL-1, TNF, and nitric oxide synthase 2 [NOS2]), and increased the expression of anti-inflammatory genes (i.e., YM1, Arg1, and MRC1) in infiltrated macrophages from WT mice but not in Mac-DP1 KO mice (Fig. 3, H and I), indicating that niacin promoted M2 polarization in infarcted hearts through DP1.
Accordingly, niacin dramatically restored cardiac function and tissue damage in WT mice but not in Mac-DP1 KO mice after MI (Fig. 3 , J and K, Table 1 and Supplemental Fig. 2 ).
Since DP1 activation may have gender differential responses in vasculature in mice(Song et al., 2012), we also compared the effect of Mac-DP1 deletion in cardiac recovery after MI between male and female mice. Again, Mac-DP1 deficiency markedly impaired cardiac recovery after MI in mice (Supplemental Table 1 ), but we failed to observe significant differences of heart functions between male and female Mac-DP1 KO mice before and after MI ( Supplemental Table 1 ).
Niacin modulates peripheral monocyte polarization in both mice and humans
We also examined the effects of niacin (600 mg/kg) on polarization of peripheral monocytes in LPS-challenged mice (Fig. 4A ). Expression of L-PGDS and DP2 were relatively low in mouse peripheral monocytes (Fig. 4, B-D) . Interestingly, niacin enhanced H-PGDS and DP1 expression in peripheral blood monocytes (CD45 + CD11b + Ly6G -Ly6C + ; Fig. 4 , B-D), but did not affect L-PGDS or DP2 expression ( Fig. 4, B-D) . As anticipated, LPS challenge induced pro-inflammatory M1 gene expression, which was blunted by niacin pretreatment in WT PMNs but not in Mac-DP1 KO PMNs (Fig. 4E ). Moreover, niacin was only able to augment anti-inflammatory M2 gene expression in WT monocytes, while DP1-deficient cells were unaffected (Fig. 4F) . Next, to determine whether niacin had the same effects in humans, blood and urine samples were collected from healthy volunteers before and after a 3-day administration of niacin (Fig. 5A ). As previously described (Song et al., 2008) , niacin treatment resulted in substantial PGD2 production ( Fig. 5B) . Interestingly, H-PGDS and lipocalin-type PGDS (L-PGDS) expression levels were significantly increased in human CD14 + PMNs, but no significant effects were observed with respect to DP1 expression ( Fig. 5, C and D) .
Accordingly, niacin induced the downregulation and upregulation of M1 and M2 markers, respectively, in human PMNs (Fig. 5 , E and F), indicating that niacin also promoted human monocyte M2 polarization.
DISCUSSION
Niacin has been used in the treatment of dyslipidemia (Carlson and Oro, 1962; Carlson, 1963) ; however, adverse effects, including facial flushing, limit its use in part by enhancing PGD2 synthesis (Dunbar and Gelfand, 2010; Hanson et al., 2010) . Here, we found that niacin facilitated post-MI healing through PGD2 receptor DP1-induced M2 polarization and resolution of inflammation.
PGD2 is involved in the resolution of inflammation (Gilroy et al., 1999) . Consistent with this, H-PGDS deficiency results in impaired inflammatory resolution in mice (Rajakariar et al., 2007) , and the pro-resolution effects of PGD2 are believed to contribute to balancing the secretion of pro-versus anti-inflammatory cytokines through DP1 receptor (Rajakariar et al., 2007) . We found that PGD2 promotes M2 polarization and , 2006) . Accordingly, in this study, we showed that niacin promoted the resolution of inflammation and cardiac recovery from ischemia by activating DP1. In accordance with these observations, niacin inhibits various inflammatory reactions in different disease models (Godin et al., 2012) .
Immediate-release niacin has been show to ameliorate lipid profiles and improve outcomes in patients with acute myocardial infarction (Canner et al., 1986; Carlson and Rosenhamer, 1988) hypertensive responses, and increases high-fat diet-induced atherosclerosis (Song et al., 2012; Strack et al., 2013) . Moreover, the PGD2-DP1 axis mediates the cardioprotective effects of glucocorticoids against ischemia-reperfusion injury (Tokudome et al., 2009; Katsumata et al., 2014) , and we found that DP1 expression in macrophages facilitates cardiac healing after MI by accelerating resolution (Kong et al., 2016) . Thus, it is possible that DP1 inhibition by laropiprant could block the beneficial effects of niacin in mice with myocardial infarction. Indeed, in the HPS2-THRIVE trial, laropiprant was found to contribute to some serious adverse events, such as excessive bleeding and infection,
given that laropiprant has high affinity for the thromboxane A2 receptor (Dallob et al., 2011) and that PGD2 has multiple anti-inflammatory properties.
In summary, our findings showed that niacin promoted cardiac recovery after MI through DP1-mediated M2 polarization and timely resolution of inflammation, suggesting activation of DP1 receptor may represent novel strategy for management of cardiovascular disease. 
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